(2S,4S)-4-[2-(4-fluorophenyl)-1,1-dimethylethylcarbamoyl]-2-methyl-4-[4-(5-methylthiazol-2-yl)benzoylamino]butyric acid | 1621924-12-6

• 英文名称: (2S,4S)-4-[2-(4-fluorophenyl)-1,1-dimethylethylcarbamoyl]-2-methyl-4-[4-(5-methylthiazol-2-yl)benzoylamino]butyric acid
• 英文别名: (2S,4S)-5-[[1-(4-fluorophenyl)-2-methylpropan-2-yl]amino]-2-methyl-4-[[4-(5-methyl-1,3-thiazol-2-yl)benzoyl]amino]-5-oxopentanoic acid
• CAS: 1621924-12-6
• 化学式: C₂₇H₃₀FN₃O₄S
• 分子量: 511.617
• InChiKey: FFZNFBWTUAFYFX-AOMKIAJQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  36
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  137
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• [EN] SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AS AGGRECANASE INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS<br/>[FR] DÉRIVÉS D'ACIDE CARBOXYLIQUE SUBSTITUÉS À TITRE D'INHIBITEURS D'AGGRÉCANASE POUR TRAITER L'ARTHROSE
  申请人：MERCK PATENT GMBH

  公开号：WO2014121884A1

  公开（公告）日：2014-08-14

  The present invention relates to compounds of the formula (I) and in particular medicaments comprising at least one compound of the formula (I) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which ADAMTS5 is involved, in particular for use in the treatment and/or prophylaxis of osteoarthritis, hepatocirrhosis, traumatic cartilage injuries, pain, allodynia or hyperalgesia.

  本发明涉及式(I)的化合物，特别是包含至少一种式(I)化合物的药物，用于治疗和/或预防涉及ADAMTS5参与的生理和/或病理生理状态，在特别用于治疗和/或预防骨关节炎、肝硬化、创伤性软骨损伤、疼痛、痛觉过敏或疼痛过敏的治疗和/或预防中。
• SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AS AGGRECANASE INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS
  申请人：MERCK PATENT GMBH

  公开号：US20150368188A1

  公开（公告）日：2015-12-24

  The present invention relates to compounds of the formula I and in particular medicaments comprising at least one compound of the formula I for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which ADAMTS5 is involved, in particular for use in the treatment and/or prophylaxis of osteoarthritis, hepatocirrhosis, traumatic cartilage injuries, pain, allodynia or hyperalgesia.

  本发明涉及公式I的化合物，特别是包括至少一种公式I的化合物的药物，用于治疗和/或预防生理和/或病理状态，在其中ADAMTS5参与诱发，特别是用于治疗和/或预防骨关节炎、肝硬化、创伤性软骨损伤、疼痛、触发性痛或过敏性痛。
• US9656949B2
  申请人：——

  公开号：US9656949B2

  公开（公告）日：2017-05-23